pSb_init containing anti SARS-CoV-2_RBD sybody Sb#15 Citations (3)

Originally described in: Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain
Walter JD, Hutter CAJ, Zimmermann I, Earp JD, Egloff P, Sorgenfrei M, Hürlimann LM, Gonda I, Meier G, Remm S, Thavarasah S, Plattet P, Seeger MA BioRxiv 2020.04.16.045419 Journal

---

Articles Citing pSb_init containing anti SARS-CoV-2_RBD sybody Sb#15

Articles
Structures of synthetic nanobody-SARS-CoV-2-RBD complexes reveal distinct sites of interaction and recognition of variants. Margulies D, Ahmad J, Jiang J, Boyd L, Zeher A, Huang R, Xia D, Natarajan K. Res Sq. 2021 Jun 16. doi: 10.21203/rs.3.rs-625642/v1. PubMed
Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction. Ahmad J, Jiang J, Boyd LF, Zeher A, Huang R, Xia D, Natarajan K, Margulies DH. J Biol Chem. 2021 Oct;297(4):101202. doi: 10.1016/j.jbc.2021.101202. Epub 2021 Sep 16. PubMed
Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. Walter JD, Scherer M, Hutter CAJ, Garaeva AA, Zimmermann I, Wyss M, Rheinberger J, Ruedin Y, Earp JC, Egloff P, Sorgenfrei M, Hurlimann LM, Gonda I, Meier G, Remm S, Thavarasah S, van Geest G, Bruggmann R, Zimmer G, Slotboom DJ, Paulino C, Plattet P, Seeger MA. EMBO Rep. 2022 Apr 5;23(4):e54199. doi: 10.15252/embr.202154199. Epub 2022 Mar 7. PubMed

If you have published an article using this material, please email us at to have your article added to this page.